Found: 1
Select item for more details and to access through your institution.
A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01).
- Published in:
- Neuro-Oncology, 2020, v. 22, n. 12, p. 1851, doi. 10.1093/neuonc/noaa107
- By:
- Publication type:
- Article